Biologics and Biosimilar Overview

Therapeutic classes of biologics and biosimilars are presented, along with a list of then new approval in 2014. In a strict sense, reverse transcriptase inhibitors and tyrosine kinase inhibitors are small molecules; they are listed as biologics in light of their biochemical attributes and that genetic screening is often required in the clinical application.

In alphabetical order, biologics are therapeutically classified as Anticoagulant/Coagulant, Antisense Products, Colony Stimulating Factors, Erythropoietin, Human Growth Hormone, Interferons, Interleukins, Reverse Transcriptase Inhibitors, Tissue Necrosis Factors, and Tyrosine Kinase Inhibitors. Biosimilar products largely overlay with the original biologics, however with smaller numbers. A list of then new approved biologics are listed (in 2014), but they are not updated as of this date.